Lomass Soliman | Young Researcher Award | Pharmaceutical Sciences

Young Researcher Award

 Lomass Soliman
Affiliation Institute of Pharmaceutical Technology and Regulatory Affairs
Country Hungary
Scoholar ID 6osAAAAJ
Documents 5
Citations 23
h-index 3
Subject Area Pharmaceutical Sciences
Event International Research Awards on Network Science & Graph Analytics

Lomass Soliman
Institute of Pharmaceutical technology and regulatory affairs

 Lomass Soliman The recognition is associated with the International Research Awards on Network Science & Graph Analytics and is intended to highlight emerging researchers whose scholarly activities demonstrate developing expertise, research engagement, and potential for continued contribution to their discipline.

Abstract

This academic recognition profile presents Lomass Soliman in the context of the Young Researcher Award. Soliman is affiliated with the Institute of Pharmaceutical Technology and Regulatory Affairs at the University of Szeged in Hungary and works within the broad field of pharmaceutical sciences. The supplied scholarly indicators record five documents, 23 citations, and an h-index of 3. These metrics describe an emerging publication and citation record and may be considered alongside the quality, originality, relevance, and documented contribution of individual research outputs. Bibliometric indicators are generally most informative when interpreted together with qualitative evidence of scholarly contribution rather than as standalone measures of research quality. [2]

Keywords

  • Lomass Soliman
  • Young Researcher Award
  • Pharmaceutical Sciences
  • Pharmaceutical Technology
  • Regulatory Affairs
  • University of Szeged
  • Research Recognition
  • Bibliometric Indicators

Introduction

Young researcher recognition generally emphasizes the development of an independent scholarly profile, research productivity, methodological competence, and potential for sustained contribution. Within pharmaceutical sciences, research may encompass drug development, pharmaceutical formulation, delivery systems, analytical methods, manufacturing technologies, quality considerations, and regulatory frameworks. The Institute of Pharmaceutical Technology and Regulatory Affairs at the University of Szeged provides an academic setting relevant to these interdisciplinary areas.

Evaluation of early-career researchers benefits from combining quantitative measures with qualitative assessment. Publication counts and citation indicators can provide useful evidence of scholarly visibility, while peer-reviewed research, methodological rigor, originality, reproducibility, and relevance offer additional dimensions for evaluation. [1]

Research Profile

Lomass Soliman’s supplied academic information places the researcher within Pharmaceutical Sciences, with an institutional affiliation in pharmaceutical technology and regulatory affairs. The available Google Scholar identifier is BPP-6osAAAAJ, while the supplied bibliometric record reports five documents, 23 citations, and an h-index of 3. [3]

The combination of pharmaceutical technology and regulatory affairs represents an interdisciplinary research environment in which scientific development can intersect with formulation, product quality, evaluation, and regulatory considerations. Further assessment of the research profile would appropriately consider the specific topics, study designs, venues, and contribution statements associated with the documented publications.

Research Contributions

Based on the supplied information, Soliman’s research profile is situated within pharmaceutical sciences and the institutional domain of pharmaceutical technology and regulatory affairs. The available record supports recognition of an emerging scholarly trajectory rather than a definitive assessment of a specific research breakthrough. Detailed contribution analysis should examine the originality, scientific methodology, reproducibility, and practical or regulatory relevance of individual publications.

  • Development of scholarly activity within pharmaceutical sciences.
  • Engagement with research at the intersection of pharmaceutical technology and regulatory affairs.
  • Establishment of an emerging citation and publication record.
  • Potential for continued interdisciplinary research and professional development.

Publications

The supplied profile reports five scholarly documents associated with the researcher. Individual publication titles, journals, publication years, authorship positions, and DOI identifiers were not provided in the source information supplied for this page. Consequently, specific publications and DOI records should be verified against authoritative bibliographic databases before being added to a formal publication list. This approach avoids attributing publications or identifiers without adequate source verification.

Research Impact

The supplied metrics indicate 23 citations across five documents and an h-index of 3. Citation counts can provide an indication of scholarly uptake, but their interpretation depends on field, publication age, document type, collaboration patterns, and database coverage. [2] For a young researcher, these indicators may be considered as part of a broader assessment that includes research quality, contribution to collaborative projects, methodological development, and prospects for future work.

Award Suitability

Lomass Soliman’s supplied academic profile is consistent with the general concept of a Young Researcher Award because it documents active scholarly work in Pharmaceutical Sciences and an identifiable record of publications and citations. The affiliation with the University of Szeged further establishes an academic research context. Final award eligibility and selection, however, should be determined according to the official criteria of the International Research Awards on Network Science & Graph Analytics and through the event’s formal review process.

Relevant evaluation may include the quality and originality of publications, demonstrated research contribution, academic progression, scholarly visibility, and the potential for continued impact. The current bibliometric indicators can serve as supporting evidence but should not substitute for peer or committee assessment.

Conclusion

Lomass Soliman represents an emerging researcher in Pharmaceutical Sciences affiliated with the University of Szeged in Hungary. The supplied record of five documents, 23 citations, and an h-index of 3 provides a measurable foundation for evaluating early scholarly development.

Within the Young Researcher Award context, the profile may be considered alongside publication quality, research originality, contribution, and future potential. Further bibliographic verification and review of individual research outputs would strengthen a comprehensive assessment.

References

  1. International Committee of Medical Journal Editors. (n.d.). Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals.https://www.icmje.org/recommendations/
  2. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.https://doi.org/10.1073/pnas.0507655102
  3. Google Scholar. (n.d.). Google Scholar profile: Lomass Soliman, profile ID BPP-6osAAAAJ.https://scholar.google.com/citations?hl=en&user=BPP-6osAAAAJ
  4. University of Szeged. (n.d.). Institute of Pharmaceutical Technology and Regulatory Affairs.https://www.u-szeged.hu/

Nikhil Sudhir Sathe | Biological Networks | Best Researcher Award

Dr. Nikhil Sudhir Sathe | Biological Networks | Best Researcher Award

Reliance Life Sciences Pvt Ltd | India

Dr. Nikhil Sudhir Sathe (PhD), currently associated with Laboratory Animal Research Services (LARS), is a distinguished researcher with over 20 years of expertise in drug discovery and preclinical evaluation of new chemical entities. His extensive professional experience encompasses in vitro genotoxicology, cell and microbial culture (aerobic, anaerobic, and viral systems including rabies virus), and small laboratory animal studies. Throughout his career at Reliance Life Sciences, Vimta Labs, Dabur Research Centre, and Wockhardt Research Centre, Dr. Sathe has demonstrated exceptional proficiency in GLP-compliant laboratory practices, including bacterial reverse mutation, chromosomal aberration, micronucleus, ELISA, cytotoxicity, and microbial monitoring assays. His early research contributions involved innovative in vitro models for evaluating the efficacy of antimicrobial and cosmetic products. Academically, he holds a Master’s and Bachelor’s degree in Microbiology from Shivaji University, Kolhapur, both with distinction. Dr. Sathe has contributed significantly to scientific literature with publications in reputed journals such as Vaccine, Microbial Pathogenesis, Infectious Medicine, and BioMed, focusing on bacteriophage therapy and vaccine development against multidrug-resistant pathogens and SARS-CoV-2. His scholarly achievements are complemented by active participation in national conferences and workshops, reflecting his deep commitment to advancing microbiological and biomedical research.

Profiles: Scopus | Orcid | Google Scholar

Featured Publications

"Unveiling Lytic Bacteriophages as Promising Biotherapeutics for the Control of Multidrug-Resistant Pseudomonas aeruginosa", CS Nikhil Sathe, Eugene Athan, Arnab Kapat, BioMed, 2025.

"Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus", N Sathe, S Shaikh, M Bhavsar, L Parte, A Gadiparthi, S Kad, S Sensarma, Vaccine, 2024.

"Bacteriophage vB_kpnS-Kpn15: Unveiling its potential triumph against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae-Unraveling efficacy through innovative", N Sathe, C Suphioglu, E Athan, A Kapat, Microbial Pathogenesis, 2024.

"Pseudomonas aeruginosa: Infections and novel approaches to treatment “Knowing the enemy” the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment", N Sathe, P Beech, L Croft, C Suphioglu, A Kapat, E Athan, Infectious medicine 2, 2023.

"Development of a novel therapy using bacteriophages: An alternative to antibiotics", NS Sathe, Deakin University, 2023.

Eman Kamal Ahmed Abdelall | Biological Network | Best Researcher Award

Dr. Eman Kamal Ahmed Abdelall | Biological Network | Best Researcher Award

Beni-Suef University | Egypt

Dr. Eman Kamal Ahmed Abdelall is a distinguished Professor of Pharmaceutical Organic Chemistry at Beni-Suef University, Egypt, with an outstanding academic and research career spanning over three decades. She earned her Ph.D. in Pharmaceutical Organic Chemistry from Cairo University in 2006 and has since advanced through academic ranks to become a full professor in 2018. Dr. Abdelall has held several key administrative positions, including Vice Dean of Student Affairs and Vice Dean for Environmental Affairs, and currently serves as the Head of the Department of Pharmaceutical Organic Chemistry. A prolific researcher, she has published over 53 peer-reviewed papers in leading journals indexed in Scopus and Google Scholar, with notable contributions to anti-inflammatory, anticancer, and antiviral drug design. Her excellence in scientific research has earned her numerous university honors, medals of excellence, and funded research awards. Dr. Abdelall is also an active reviewer for international journals, a member of higher education promotion committees, and a mentor who has supervised multiple Master’s and Doctoral theses, making her a leading figure in Egypt’s pharmaceutical research community.

Profiles: Scopus | Orcid | Google Scholar

Featured Publications

"Molecular docking, ADME study, Cardiovascular biomarkers and gastric safety of new pyrazoles as selective anti-inflammatory agents", EKA Abdelall, SS Zaghlool, JZF Saad, JN Philoppes, Journal of Molecular Structur, 2025.

"Synthesis of new selective agents with dual anti-inflammatory and SARS-CoV-2 Mpro inhibitory activity: Antipyrine-celecoxib hybrid analogues; COX-2, COVID-19 cytokine storm and replication inhibitory activities", EKA Abdelall, HAH Elshemy, MB Labib, JN Philoppes, FEM Ali, Bioorganic Chemistry, 2025.

"Synthesis and in silico studies of Novel thiophene–celecoxib hybrid with excellent cardiotoxicity and nephrotoxicity safety profiles", EKA Abdelall, PF Lamie, MB Labib, M El-Daly, A Mishrif, European Journal of Medicinal Chemistry, 2025.

"Novel quinoxaline derivatives as promising cytotoxic agents: structure-based design, in silico studies, VEGFR-2 inhibition, and PI3K/AKT/mTOR pathway modulation", EKA Abdelall, HAH Elshemy, H Abdelmegeed, N Ryad, AA Abdelaziz, Bioorganic Chemistr, 2025.

"The Role of Clinical Pharmacist in Monitoring Drug Therapy in the Cardiovascular and Coronary Care Units in Libya", ASH Alhomri, AA Battah, AA Elberry, EKA Abdelall, R Hussein", Pharmacy Practice, 2024.

Vijaykumar Nimbarte | Medicinal Chemistry | Best Researcher Award

Dr. Vijaykumar Nimbarte | Medicinal Chemistry | Best Researcher Award

BITS Pilani Hyderabad Campus | India

Author Profiles

Scopus

Google Scholar

Early Academic Pursuits

Dr. Vijaykumar Nimbarte began his academic journey with a Bachelor’s degree in Pharmaceutical Sciences from Nagpur University, India, where he acquired foundational knowledge in pharmaceutics, pharmacology, pharmaceutical chemistry, and pharmacognosy. He further advanced his expertise with an M.S. in Medicinal and Pharmaceutical Chemistry from NIPER Hyderabad, India, focusing on the design, synthesis, and biological evaluation of novel soluble epoxide hydrolase inhibitors with anti-inflammatory potential. During this period, he received the NIPER research assistantship and GPAT fellowship and participated in multiple drug discovery workshops, laying a strong foundation in medicinal chemistry. His Ph.D. at Goethe University, Germany, under the Marie Curie Early Stage Researcher Fellowship, focused on the design, synthesis, and evaluation of novel c-MYC G-Quadruplex stabilizing agents, earning him the highest distinction (magna cum laude).

Professional Endeavors

Following his Ph.D., Dr. Nimbarte expanded his research expertise through several key roles in international academic and industrial settings. He worked as a Project Associate in France at the University of Le Havre, where he developed azaindole-based compounds for anticancer activity. At CSIR-IICT Hyderabad, he contributed to synthesizing PBD-based intercalating agents and novel tubulin polymerase inhibitors. Most recently, he served as a Post-Doctoral Scientist at the Max Planck Institute for Medical Research, Germany, where he focused on structure-based drug design for peripheral neuropathy, collaborating with international research centers to optimize CNS-restricted drug candidates. Since January 2024, he has been an Assistant Professor of Medicinal Chemistry at BITS Pilani, Hyderabad, India.

Contributions and Research Focus

Dr. Nimbarte’s research primarily revolves around medicinal chemistry, structure-based drug design, chemical biology, and the development of biologically active small molecules. His work spans multistep organic synthesis, isotope labeling, and characterization using NMR, Mass, IR, and UV techniques. He has actively contributed to designing compounds that stabilize G-Quadruplex DNA structures, targeting cancer, and developing peripheral-restricted CNS drug candidates, addressing blood-brain barrier permeability issues. He has also applied advanced computational methods, including Schrodinger and ChemAxon software, to improve the efficiency and specificity of drug design.

Impact and Influence

With over 10 years of academic-industrial research experience, Dr. Nimbarte has significantly influenced the field of medicinal chemistry. His projects have successfully transitioned from conceptual design to lead candidate development, demonstrating his ability to combine theoretical design with practical synthesis and biological evaluation. He has collaborated internationally, mentored graduate students, led small group teaching sessions, and contributed to scientific knowledge through presentations and publications.

Academic Citations and Publications

Dr. Nimbarte has published more than 17 research papers in reputable international medicinal chemistry journals, including ChemMedChem. He has served as a potential reviewer for multiple journals such as Medicinal Chemistry Research, Bioorganic and Medicinal Chemistry Letters, Bioorganic Chemistry, and Current Medicinal Chemistry, reflecting his recognition as an expert in his field.

Legacy and Future Contributions

Dr. Nimbarte’s legacy lies in bridging the gap between academic research and practical drug discovery through innovative medicinal chemistry approaches. His work on G-Quadruplex stabilizing agents and peripherally restricted CNS drugs has paved the way for safer, more effective therapeutic candidates. Looking forward, his focus will likely continue on designing targeted small molecules with high therapeutic potential while mentoring the next generation of scientists and expanding interdisciplinary collaborations.

Conclusion

Dr. Vijaykumar Nimbarte exemplifies the integration of deep scientific knowledge, practical drug discovery experience, and academic mentorship. His early academic achievements, international research exposure, and impactful publications reflect a career dedicated to advancing medicinal chemistry. Through his innovative approaches, collaborative ethos, and commitment to teaching, he continues to make significant contributions to both the scientific community and future generations of researchers.

Notable Publications

“Understanding the Impact of Calcineurin Inhibitors on T Cell Regulation: Mechanisms and Clinical Implications

  • Author: VD Nimbarte, SS Sonak, S Ishwarkar
  • Journal: Critical Reviews
  • Year: 2025

"Modulation of T Cell Regulation by Interleukin-2 Agonists: Mechanisms and Clinical Implications

  • Author: SS Sonak, S Ishwarkar, C Nimbarte, VD Nimbarte‏
  • Journal: Critical Reviews
  • Year: 2025

"Synthesis and in Vitro Evaluation of Novel 5‐Nitroindole Derivatives as c‐Myc G‐Quadruplex Binders with Anticancer Activity

  • Author: VD Nimbarte, J Wirmer‐Bartoschek, SL Gande, I Alshamleh, M Seibert
  • Journal: ChemMedChem
  • Year: 2021

"Synthesis and Biological Screening of New Lawson Derivatives as Selective Substrate‐Based Inhibitors of Cytochrome bo3 Ubiquinol Oxidase from Escherichia coli

  • Author: I Elamri, M Radloff, KF Hohmann, VD Nimbarte, HR Nasiri, M Bolte‏
  • Journal: ChemMedChem‏
  • Year: 2020

"Anti-tyrosinase, anti-cholinesterase and cytotoxic activities of extracts and phytochemicals from the Tunisian Citharexylum spinosum L.: Molecular docking and SAR analysis

  • Author: I Saidi, VD Nimbarte, H Schwalbe, P Waffo-Teguo, AH Harrath, L Mansour
  • Journal: Bioorganic Chemistry
  • Year: 2020